Motus GI Holdings Management

Management Kriterienprüfungen 1/4

Motus GI Holdings' CEO ist Mark Pomeranz, ernannt in Apr 2023, hat eine Amtszeit von 1.08 Jahren. Die jährliche Gesamtvergütung beträgt $956.35K, bestehend aus 44.8% Gehalt und 55.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.001% der Aktien des Unternehmens, im Wert von $7.84. Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 0.9 Jahre bzw. 5.8 Jahre.

Wichtige Informationen

Mark Pomeranz

Geschäftsführender

US$956.4k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	44.8%
Amtszeit als Geschäftsführer	1.2yrs
Eigentum des Geschäftsführers	0.001%
Durchschnittliche Amtszeit des Managements	less than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.9yrs

Jüngste Management Updates

Recent updates

Motus GI regains compliance with minimum bid price requirement

Aug 11

Motus GI Holdings announces 1-for-20 reverse stock split to satisfy Nasdaq's minimum bid requirement

Jul 25

Motus GI starts enrollment in Pure-Vu System EU study

Jun 16

Motus GI shares rocket 55% on FDA 510(k) clearance of Pure-Vu System

Apr 30

Here's Why Motus GI Holdings (NASDAQ:MOTS) Can Manage Its Debt Despite Losing Money

Mar 02

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Mark Pomeranz im Vergleich zu den Einnahmen von Motus GI Holdings verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	-US$16m
Dec 31 2023	US$956k	US$428k	-US$13m
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$516k	US$385k	-US$19m
Sep 30 2022	n/a	n/a	-US$20m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$858k	US$385k	-US$25m
Sep 30 2021	n/a	n/a	-US$25m
Jun 30 2021	n/a	n/a	-US$24m
Mar 31 2021	n/a	n/a	-US$24m
Dec 31 2020	US$825k	US$385k	-US$19m
Sep 30 2020	n/a	n/a	-US$21m
Jun 30 2020	n/a	n/a	-US$22m
Mar 31 2020	n/a	n/a	-US$23m
Dec 31 2019	US$1m	US$385k	-US$23m
Sep 30 2019	n/a	n/a	-US$23m
Jun 30 2019	n/a	n/a	-US$23m
Mar 31 2019	n/a	n/a	-US$21m
Dec 31 2018	US$502k	US$359k	-US$22m
Sep 30 2018	n/a	n/a	-US$20m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	n/a	n/a	-US$18m
Dec 31 2017	US$2m	US$350k	-US$13m

Vergütung im Vergleich zum Markt: MarkDie Gesamtvergütung ($USD956.35K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD667.11K).

Entschädigung vs. Einkommen: MarkDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Mark Pomeranz (62 yo)

1.2yrs

Amtszeit

US$956,353

Vergütung

Mr. Mark Pomeranz serves as Chief Executive Officer of Motus GI Holdings, Inc. since April 13, 2023. He had been President and Chief Operating Officer of Motus GI Holdings Inc. since September 24, 2018 unt...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Mark Pomeranz	Non-Independent Director & CEO	1.2yrs	US$956.35k	0.00099% $ 3.2
Ravit Ram	CFO & VP of Global Operations	less than a year	US$419.14k	0% $ 0
Elad Amor	Chief Accounting Officer	less than a year	US$378.40k	0% $ 0

1.0yrs

Durchschnittliche Betriebszugehörigkeit

49yo

Durchschnittliches Alter

Erfahrenes Management: MOTSDas Führungsteam des Unternehmens gilt nicht als erfahren (0.9 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Mark Pomeranz	Non-Independent Director & CEO	10.4yrs	US$956.35k	0.00099% $ 3.2
Steven Edmundowicz	Member of Medical Advisory Board	no data	keine Daten	keine Daten
David Lieberman	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Gary John Pruden	Independent Director	6.5yrs	US$52.25k	0.013% $ 41.2
Scott Durbin	Director	less than a year	US$18.38k	keine Daten
Seth Gross	Member of Advisory Board	6.1yrs	keine Daten	keine Daten
Sonja Nelson	Independent Director	3yrs	US$53.90k	0.0058% $ 18.7
Ian Gralnek	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Brian Jacobson	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Peter Siersema	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Gerald Bertiger	Member of Medical Advisory Board	no data	keine Daten	keine Daten
Timothy Moran	Independent Chairman	5.7yrs	US$40.80k	0.0037% $ 11.8

5.9yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrener Vorstand: MOTSDie Vorstandsmitglieder gelten als erfahren (5.8 Jahre durchschnittliche Amtszeit).

Motus GI Holdings Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Motus GI Holdings, Inc. Announces Executive Changes

Motus GI Holdings, Inc., Annual General Meeting, Sep 21, 2023

Shervin Korangy Resigns from the Board of Directors of Motus GI Holdings, Inc

Motus GI Holdings, Inc. Announces Executive Changes

Insufficient new directors

Motus GI Holdings, Inc., Annual General Meeting, Jun 30, 2022

Recent updates

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from S&P TMI Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings, Inc.(OTCPK:MOTS) dropped from NASDAQ Composite Index

Motus GI Holdings Receive Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(a)(2)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings, Inc. Publishes Positive Results from A European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with A History of Poor Bowel Preparation

Consensus EPS estimates upgraded to US$24.75 loss, revenue downgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings, Inc. Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu®? EVS Gastro

Motus GI Holdings, Inc. Receives Fda Clearance to Commercialize Pure-Vu Evs Gastro and Gen 4 Colon

New minor risk - Share price stability

Motus GI Holdings Announces Update on Non-Compliance with Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Motus GI Holdings, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 23%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings, Inc. Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of Its Pure-Vu® EVS System

Motus GI Holdings, Inc., Annual General Meeting, Sep 21, 2023

Shervin Korangy Resigns from the Board of Directors of Motus GI Holdings, Inc

Motus GI Holdings Provides Shareholder's Equity Compliance Update

Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 At the Pentax Learning Center

Motus GI Holdings, Inc. Announces Executive Changes

Consensus EPS estimates upgraded to US$2.48 loss

Motus GI Holdings, Inc. announced that it expects to receive $3.5 million in funding

Motus GI Holdings, Inc. Completes First Clinical Evaluation of New Pure-Vu(R) Gastro in Upper Gastrointestinal Procedures to Support Fda Submission

Price target increased by 58% to US$10.00

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Holdings Receives Non-Compliance Notice From Nasdaq

Motus GI Holdings, Inc. Announces Improvement of Pure-Vu® EVS System for Use in Upper Gastrointestinal (GI) Bleeding Procedures Following Successful Pre-Clinical Tests

Consensus revenue estimates fall by 22%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Insufficient new directors

Motus GI Holdings, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Motus GI Regains Compliance with Nasdaq Minimum Bid Price Requirement

Motus GI regains compliance with minimum bid price requirement

Motus GI Holdings announces 1-for-20 reverse stock split to satisfy Nasdaq's minimum bid requirement

Motus GI Holdings, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings Announces Positive Topline Data from EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Motus GI Holdings, Inc., Annual General Meeting, Jun 30, 2022

Consensus forecasts updated

Price target decreased to US$1.43

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Motus GI Completes Enrollment in the European Union Feasibility Study of the Pure-Vu System as a New Method for Bowel Cleansing in Patients with a History of Poor Bowel Preparation

Price target decreased to US$1.73

Consensus EPS estimates fall by 13%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Motus GI Grants 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement

Motus GI Holdings, Inc. Receives FDA Clearance to Market the Pure-Vu® EVS System

Price target decreased to US$1.86

Third quarter 2021 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2020)

Insufficient new directors

Independent Director Samuel Nussbaum has left the company

Second quarter 2021 earnings released: US$0.099 loss per share (vs US$0.15 loss in 2Q 2020)

Consensus forecasts updated

Motus GI Announces First Patients Enrolled in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients With a History of Poor Bowel Preparation

Motus GI starts enrollment in Pure-Vu System EU study

Consensus forecasts updated

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.23 loss in 1Q 2020)

Price target decreased to US$2.24

Motus Gi Holdings, Inc. Announces Publication of A Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource

Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy

Motus GI shares rocket 55% on FDA 510(k) clearance of Pure-Vu System

Consensus forecasts updated